Mon.Aug 19, 2024

article thumbnail

Opinion: Private equity: health care’s vampire

STAT

Private equity firms are sucking the resources out of America’s hospitals and nursing homes, and feeding on doctors to generate profits. These firms — which pool funds from wealthy investors and are exempt from many of the regulations and disclosure requirements that apply to other types of investments — have spent a half-trillion dollars since 2018 buying up medical resources.

article thumbnail

BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings

PharmaVoice

With fewer side effects, the new wave of upcoming drugs could improve patient adherence, and the competition for a large projected market is getting fierce.

173
173
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Study exposes the dangerous ‘hidden’ mental burden of cancer on patients’ spouses

STAT

The distress from receiving a cancer diagnosis is something that clinicians widely anticipate in patients, but suffering often doesn’t just afflict the patient. It can blanket an entire household, burdening spouses and other family members with stress and anxiety and the exhausting routine of treating a life-threatening disease. But while standards exist for assessing and managing distress in patients, it’s often “hidden” in family members, sometimes with devastating

363
363
article thumbnail

EM Match Advice 45: 2024 MyERAS Updates– What EM Applicants Need to Know

ALiEM - Pharm Pearls

Dr. Sara Krzyzaniak, EM Match Advice Podcast Host and Stanford University PD, discusses key changes in the 2024 MyERAS (Electronic Residency Application Service) application that all EM applicants should know about. Take a listen to this short 14-minute, high-yield episode before submitting your application. Podcast 45: Key 2024 MyERAS updates Highlights Hometown preferences are now limited to 3 (no longer 5).

152
152
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

STAT+: AI drug firm Recursion moves from survival to industry domination

STAT

SALT LAKE CITY — On paper, Recursion Pharmaceuticals shouldn’t have worked. The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased cells, and use that data to identify drugs gathering dust on pharmaceutical company shelves that could be repurposed as rare disease treatments.

article thumbnail

Novo plans new plant as it races to meet drug demand

PharmaVoice

The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.

130
130

More Trending

article thumbnail

Pharmacy crises highlighted in 'honest' NHS review

The Pharmacist

Pharmacy bodies have highlighted funding, workforce and medicine supply concerns to an independent review intended to 'diagnose' the challenges facing the NHS. Health and social care secretary Wes Streeting has commissioned the Darzi review to deliver 'a raw and frank assessment of the state of the NHS' next month. 'This is the necessary first step […] The post Pharmacy crises highlighted in 'honest' NHS review appeared first on The Pharmacist.

109
109
article thumbnail

Opinion: Graphic mpox images to educate the public are deeply problematic

STAT

For the second time in three years, the WHO has declared an mpox outbreak a public health emergency of international concern. Since news of the epidemic, the media has circulated images of patients infected with mpox. Some of these photographs show mpox on patients’ arms, legs, and hands, but others are headshots that resemble mugshots of African people with mpox covering their faces.

353
353
article thumbnail

US govt taps Walgreens for decentralised trials

pharmaphorum

Walgreens has signed a $100m contract with the US government's BARDA agency for access to its decentralised clinical trials network

132
132
article thumbnail

STAT+: Another suit filed against FDA over lab-developed test rule

STAT

A group representing molecular pathologists sued the Food and Drug Administration on Monday over its plan to regulate lab-developed tests.  It’s the second legal challenge to the rule, following the American Clinical Laboratory Association’s suit in May. The suit, filed in Texas by the Association for Molecular Pathology and University of Texas pathologist Michael Laposata, claims that the FDA overstepped its regulatory bounds when deciding to regulate lab-developed tests.

292
292
article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

JP Nadda inaugurates First Policy Makers’ forum in New Delhi

Express Pharma

Union Minister of Chemicals and Fertilizers, and Health and Family Welfare, JP Nadda inaugurated the ‘First Policy Makers’ Forum’, which will run until August 22, 2024. To elevate India’s position in the global pharmaceutical sector, the Indian Pharmacopoeia Commission (IPC), in collaboration with the MoHFW and the Ministry of External Affairs (MEA), hosted an international delegation of policymakers and drug regulators from 15 countries.

article thumbnail

STAT+: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?

STAT

As the Federal Trade Commission scrutinizes the pharmaceutical industry, there is growing debate about whether the regulator may next target a deal that some experts say could make it easier for Novo Nordisk to boost production of a key drug — at the expense of competitors. At issue is a complicated transaction sparked by sporadic shortages of one of the world’s hottest-selling medications — the weight loss treatment Wegovy.

302
302
article thumbnail

As Bristol Myers’ schizophrenia drug nears approval, AbbVie and others hope to provide competition

BioPharma Dive

A new wave of antipsychotics could improve patient adherence. The race to corner this large projected market is already getting tight.

116
116
article thumbnail

Patient volumes have stormed back into hospitals

STAT

You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. A self-interested plea from Peter Orszag Peter Orszag, CEO of Lazard, went on CNBC last week and criticized how the Federal Trade Commission and Department of Justice were gumming up health care mergers.

Hospitals 267
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

Waters Corporation appoints Heather Knight to board of directors

Express Pharma

Waters Corporation announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. She brings nearly three decades of experience across the pharma and medical device industries, and a track record of driving strong execution, business transformation, and portfolio innovation.

104
104
article thumbnail

Eli Lilly acquires Morphic in IBD portfolio expansion

Pharmaceutical Technology

Eli Lilly has concluded the acquisition of Morphic Holding at $57 per share, bolstering its inflammatory bowel disease portfolio.

105
105
article thumbnail

Nature publishes new research on genetic causes of colorectal cancer

Pharma Times

In the UK study, researchers analysed 2,023 bowel cancers from the 100,000 Genomes Project

111
111
article thumbnail

South African president calls on WHO for better mpox response

Pharmaceutical Technology

Cyril Ramaphosa, the president of South Africa, has asked the WHO to ensure African countries have equitable access to mpox vaccines.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Oncimmune announces new contract with global pharma company

Pharma Times

The contract concerns profiling Immunoglobulin E autoantibodies in blood serum

111
111
article thumbnail

Sound Pharmaceuticals plans to stick with WuXi amid BIOSECURE Act rumblings

Pharmaceutical Technology

Looking to potentially market their flagship drug SPI-1005, Sound CEO Jonathan Kil is keen to retain WuXi AppTec as a partner.

98
article thumbnail

Safeguarding patient data: Four steps to consider when assessing your IT infrastructure

pharmaphorum

Safeguarding patient data is crucial in the healthcare industry. This article outlines four steps to consider when assessing your IT infrastructure to protect against ransomware and ensure the security of patient data.

70
article thumbnail

Researchers make breakthrough in fight against COVID-19

World Pharma News

A team led by Jose Onuchic at Rice University and Paul Whitford at Northeastern University, both researchers at the National Science Foundation Physics Frontiers Center at the Center for Theoretical Biological Physics (CTBP) at Rice, has made a discovery in the fight against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus responsible for COVID-19.

71
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

EU starts review of Enhertu in HER2-ultra-low breast cancer

pharmaphorum

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 biomarker.

60
article thumbnail

EMA validates Type II Variation application for ENHERTU for breast cancer treatment

Pharmaceutical Business Review

ENHERTU, a HER2 directed a DXd antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being jointly developed and commercialised by Daiichi Sankyo with AstraZeneca. The EMA’s validation of the application signifies the commencement of a detailed scientific evaluation by its Committee for Medicinal Products for Human Use. The application for ENHERTU is supported by data from the DESTINY-Breast06 Phase III trial, which was highlighted at the 2024 American Society of Clinical

article thumbnail

Pfizer and BioNTech's COVID/flu vaccine hits a hurdle

pharmaphorum

Pfizer and BioNTech have a phase 3 mishap with their combined COVID-19 and influenza vaccine, handing Moderna an advantage

article thumbnail

Novo plans new plant as it races to meet drug demand

BioPharma Dive

The new factory, which Novo is committing some $220 million to build, will supply raw materials for the company’s chronic disease medicines.

62
article thumbnail

New tentative approval for Alembic drug dabigatran etexilate mesylate

Drug Patent Watch

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.

52
article thumbnail

FDA lifts partial hold on study of BioNTech-partnered ADC

BioPharma Dive

Partner MediLink Therapeutics is limiting the drug’s dosing after reports of lowered white blood cell counts and inflammation of the digestive tract.

57
article thumbnail

Leveraging AI for the Benefit of Patients

Pharmaceutical Commerce

In an interview with Pharma Commerce Editor Nicholas Saraceno, Matt Hawkins, CaryHealth’s Chief Technology Officer, describes how artificial intelligence can not only diagnose patients, but also deliver accurate medical advice.

52
article thumbnail

FDA Approves AstraZeneca’s Imfinzi in Combination with Chemotherapy for Resectable Early-Stage Non-Small Cell Lung Cancer

PharmExec

The combination treatment involves administering Imfinzi with neoadjuvant chemotherapy for non-small cell lung cancer before surgery and as monotherapy post-surgery.

article thumbnail

The Economics of Generic Drug Pricing Strategies: A Comprehensive Analysis

Drug Patent Watch

The pricing of generic drugs is a crucial aspect of the pharmaceutical industry, with significant implications for consumers and healthcare […] Source

article thumbnail

FDA Approves Incyte and Syndax Pharmaceuticals’ Niktimvo for Treating Chronic Graft-Versus-Host Disease

PharmExec

Approval of Niktimvo was based on positive data from the AGAVE-201 study, which demonstrated a 75% response rate in patients with chronic graft-versus-host disease.

52